Objective: Research is lacking on the natural history of acute pancreatitis (AP) progression to acute recurrent pancreatitis (ARP). The aim of this project was to study the progression from AP to ARP among pediatric patients with pancreatitis to better understand the presentation and natural history of pancreatitis. Methods: PatientspresentingwithAPwereincludedinaprospectivedatabasein Research Electronic Data Capture. We enrolled 115 patients with AP from March2013 toNovember2016. Physicians completed surveys regarding clinical data for patients with first attack of AP. Patients were followed prospectively, with data on progression entered when patients presented with ARP. Results: The most common etiologies for the first attack of AP were idiopathic (31%), toxic/drug-related (23%), and biliary/gallstone (18%). Twenty of the 115 patients (17%) developed ARP during the follow-up period. Seventy percent (14/20) of patients with ARP progressed from AP to ARP within 5 months from first diagnosis. A comparison of patients who rapidly progressed to ARP within 3 months (n ¼ 12) to those followed for >3 months without progression in 3 months (n ¼ 97) revealed associations with a higher weight percentile for age (P ¼ 0.045), male sex (P ¼ 0.03), and presence of pancreatic necrosis during first AP attack (P ¼ 0.004). Progression to ARP significantly differed by etiology group with genetics having the highest risk for ARP progression over time and patients with gallstone/biliary, viral/systemic, and obstructive (nongallstone) having the lowest risk for ARP progression over time (P ¼ 0.02). Conclusions: Most patients who progressed from AP to ARP progressed within 5 months. The presence of a higher weight percentile for age, male sex, and pancreatic necrosis during the first AP attack are associated with rapid progression to ARP.
A cute pancreatitis (AP) in the pediatric population has increased in incidence to the current estimate of up to 13/ 100,000 (1) over the last 2 decades. The factors leading to this increase appear to be multifactorial, and include increased surveillance with a greater referral to tertiary care centers, and increased incidence of systemic illnesses complicated by pancreatitis in the pediatric population (1) (2) (3) (4) (5) . Despite this trend, AP remains a poorly understood clinical entity in pediatrics.
Prospective clinical research is lacking on both the natural history of AP and factors influencing progression of disease to acute recurrent pancreatitis (ARP). A 2011 review by Bai et al highlights this issue (6) , and notably the majority of previous studies of AP are single-centered and retrospective in nature (3, 4, (7) (8) (9) (10) (11) (12) (13) . Retrospective data previously published restrict the ability to predict which patients with AP are at greater risk for advancement to ARP.
The International Study Group for Pediatric Pancreatitis: In Search for a Cure (INSPPIRE) is a multicenter study primarily focused on ARP and chronic pancreatitis (CP) in pediatrics. The consortium has published the now widely accepted definitions of AP, ARP, and CP in children (14) . Today we lack data on the inciting events which lead to ARP/CP starting with the first episode of AP and the clinical characteristics of those who progress to ARP.
What Is Known
Pancreatitis is increasing in incidence among pediatric patients. The natural history of pancreatitis in pediatric patients is poorly understood. It is unknown which patients will progress to acute recurrent or chronic pancreatitis after the first acute pancreatitis episode.
What Is New
This is the first prospective study following children after first attack of acute pancreatitis delineating the course. Rapid acute recurrent pancreatitis according to our study is defined as: 2 attacks with at least 1-month free interval, but within 3 months of initial attack, is associated with male sex, patients with higher weight percentile or presence of pancreatic necrosis in the initial attack. A novel finding from our cohort, the majority of recurrent pancreatitis attacks occurred within 5 months of follow-up.
Therefore, there is a remaining gap in our understanding of which children are more likely to progress from AP to ARP. Risk factors for progression in the adult population include tobacco and alcohol use; however, these exposures are the exception in pediatrics (15) . A recent multicenter cross-sectional study by INSPPIRE identified genetic mutations as a common risk factor found amongst patients with ARP and CP, and that smoking and alcohol abuse were uncommon in this population (16) .
In an effort to better understand the natural history of AP progression to ARP, we designed a novel database and registry to prospectively study characteristics of initial and recurrent AP attacks at our quaternary care center, Cincinnati Children's Hospital Medical Center (CCHMC). We primarily hypothesized that patients progressing rapidly from AP to ARP differed from patients who progressed more slowly or did not progress to ARP during the follow-up period (shortest to longest follow-up). Herein we describe a patient cohort with their first AP and followed prospectively overtime to monitor for development of ARP in children.
PATIENTS AND METHODS

Patient Population
Patients admitted to CCHMC with their first occurrence of AP or evaluated at our outpatient Pancreas Care Center for new onset pancreatitis were identified and consented for inclusion in our CCHMC IRB-approved database. From March 2013 until November 2016, a total of 115 patients with the first attack of pancreatitis were enrolled. Patients' inclusion criteria were AP diagnosis by having 2 out of 3 criteria as defined by INSPPIRE (abdominal pain characteristic of pancreatic origin, amylase and/or lipase 3 times the upper limit of normal, imaging showing evidence of pancreatitis), first attack of AP, and age less than 21 years upon enrollment. ARP is defined by 2 attacks with at least 1-month free interval, or <1 month if symptoms resolve with complete normalization of enzymes (14) . Physician completed questionnaires based on chart review were entered in REDCap (Research Electronic Data Capture). Data collected included laboratory and imaging findings, family history, risk factors, inpatient management, and interventions, as well as the clinical course and outcomes. Follow-up data on clinical progression were entered when registered patients represented with ARP.
Statistical Analysis
Data were analyzed using SAS, version 9.4 (SAS Institute, Cary, NC). Because of the sample sizes and the distribution of variables, continuous data were summarized as medians with interquartile range (IQR: 25th-75th percentiles), whereas categorical data were summarized as frequency counts with percentages. Fisher exact tests were used for the rapid progression group comparisons of categorical variables. For continuous data, nonparametric Wilcoxon-Mann-Whitney tests were used to compare characteristics between the rapid progression groups. A Cox proportional hazards model was used to analyze etiology groups and time to ARP for the whole sample. P < 0.05 was considered statistically significant for analyses.
RESULTS
Patients Presenting With First Attack of Acute Pancreatitis
A total of 115 pediatric patients with first attack AP were enrolled in our registry during the designated study period of which 52% were boys and the median age of initial AP attack was 13.5 years (IQR: 9.3-15.9) ( Table 1 ). The most common etiology was idiopathic 31% (36/115). The next common etiologies were toxic/ drug related (23%) and biliary/gallstone (18%). The follow-up period was 1.2 to 98.4 months, with a median of 21 months (IQR: 10.2-32.7).
Progression From Acute Pancreatitis to Acute Recurrent Pancreatitis
Of the 115 patients with AP, 20 (17%) progressed to ARP during the study period. The median interval from AP to ARP was 2.5 months (IQR: 1.3-6.6) and the median age at ARP development was 14.4 years (IQR: 11.0-16.4). The majority, 70% (14/20) , of the ARP patients developed ARP within 5 months of their first AP attack (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/MPG/B483). The distribution of the patient ARP second episode timing is represented in Figure 1 . Eighty percent (16/20) of these ARP patients underwent extensive genetic testing and 6/16 (38%) of those tested had a genetic mutation identified (Supplemental Table 2 , Supplemental Digital Content 2, http://links.lww.com/MPG/B484).
Rapid Progression to Acute Recurrent Pancreatitis
ARP is defined by 2 attacks with at least 1-month free interval, or <1 month if symptoms resolve with documentation of complete normalization of enzymes (15) . Given the findings that the majority of our patients progressed to ARP by 5 months with a median time interval of 2.5 months, we studied further the group of patients who had progression to ARP that occurred within 3 months of their first attack to define the characteristics and risks factors for ''more rapid progression.'' There were 109 patients with pancreatitis who were followed for at least 3 months, of which a subgroup of 12 had rapid progression to ARP and 97 with AP who did not develop ARP within 3 months (includes both those that did not progress to ARP and those who progressed to ARP !3 months after first AP attack) that were included for analysis. In comparison, the rapid progression group included 83% boys which was a significantly higher proportion than those whom did not progress to ARP within 3 months 48% (P ¼ 0.03). The median weight percentile for age was significantly higher in the rapid progression group compared to the group that did not progress within 3 months (85.2 vs 47.8, P ¼ 0.045). The proportion of pancreatic necrosis was also significantly higher in the rapid progression group (25% vs 1%, P ¼ 0.004). See Table 2 for group comparisons. We were also interested in studying the etiology or risk factors associated with the first AP occurrence and their effect on progression to ARP overtime for the whole sample. We compared patients with gallstone/biliary, trauma, viral/systemic, toxic/drug, metabolic, obstructive, and multiple etiologies if they had >1 etiology (nongenetic), genetic etiology, or idiopathic. There were n ¼ 3 patients who had both genetic and other factors (biliary/ gallstone) etiologies that were categorized as genetic for analysis purposes. We found that progression to ARP significantly differed by etiology group (P ¼ 0.02) with patients with gallstone/biliary, viral/systemic, and obstructive (nongallstone) having the lowest risk for ARP progression over time (Fig. 2) .
We also found the etiology groups significantly differed between the 3-month progression groups with a higher proportion of genetic mutations in the rapid progression group by univariate comparison (P ¼ 0.005) ( Table 3) .
DISCUSSION
We report the first prospective pediatric AP study in the United States from a database developed at our institution, following the natural history of AP, as well as outcomes and progression to ARP. Our results provide important observations on key clinical characteristics of AP, and information on the rate of progression of AP to ARP that has not been previously elucidated in retrospective study designs.
One of the strengths of our database is that it is discretely able to identify the etiology of the patient's first episode of AP, and then prospectively follow the impact of identified risk factors on disease progression. In our cohort, 31% of AP cases did not have an identified etiology or were classified as ''idiopathic,'' which is consistent with previous studies (3,6,7,11,13). The majority of our patients, 69%, had an identifiable risk factor for AP. Systemic causes were on top of the list of identifiable causes; toxic/drug (23%) and viral/systemic illness in 17% of patients. This mirrors results from previous retrospective studies that systemic disease complicated by pancreatitis is a contributor to pediatric AP (3) (4) (5) . Gallstone/biliary disease was the etiology in approximately 18% of our patients, also consistent with previous studies (6) .
We identified a total of 20 patients who progressed from AP to ARP since enrollment in the database which represents 17% of all patients with AP. This result falls within previously published recurrence rates of 7% to 34% (6) . A novel finding from our study is that the majority of the patients (70%) who developed ARP had progressed within 5 months. This finding may help in parental counseling and anticipatory guidance of pediatric patients presenting with their first AP attack, knowing that the majority of patients with ARP will meet criteria in a relatively short duration of time if they were to advance to recurrent disease. Specific genetic changes in the Cystic Fibrosis Transmembrane Regulator CFTR, SPINK1 and Cationic Trypsinogen PRSS1, and Chemotrypsin Regulator CTRC genes amongst other genes known to be causing hereditary pancreatitis are associated with a higher risk of development of ARP and CP (17) (18) (19) (20) (21) (22) (23) (24) . Of the patients in our cohort with ARP, 16 underwent genetic testing with 6 patients having been found to have a genetic mutation in a 1 of 4 gene panels (testing included PRSS1, SPINK1, CFTR, and CTRC). CFTR was the most commonly identified gene variant, followed by PRSS1 and SPINK1 consistent with previous studies (17) (18) (19) (20) (21) (22) (23) (24) . A prior study of genetic mutations in children with ARP and CP found mutations in CFTR, SPINK1, or PRSS1 in one third of patients without an additional cause for pancreatitis (25) . A limitation to our study is that genetic testing was not performed systematically on all study patients, although the majority of patients within our cohort who progressed to ARP did undergo such testing. The current practice at most pediatric institutions is to consider performing genetic testing on patients once a diagnosis of ARP or CP is made and other causes of pancreatitis have been ruled out. Our center's current standard of care is to perform genetic testing once a patient presents with their second episode of AP unless there is a strong family history of hereditary pancreatitis whereby such testing may well be performed upon the first AP occurrence. For our study purposes, the genetic results were analyzed from the number of patients who have been tested based upon individual provider practice. However, our results would support obtaining earlier and more standardized utilization of genetic testing in patients with recurrent disease as clinically relevant data.
We have also shown here that patients with gallstone/biliary, viral/systemic, and obstructive (nongallstone) were at the lowest risk for progression to ARP over time in our survival analysis compared with the other etiology groupings overall in our patient population. Genetics had the highest risk; however, this finding should be verified by future studies in which all patient subjects undergo full and complete genetic testing irrespective of provider preference.
A subset of the ARP group was identified consisting of 12 patients who progressed from their first episode of AP to ARP within 3 months, as we defined as a cut off for rapid progression categorization. The 3-month period was reasoned as clinically relevant as it fell in between the 1-month pain-free interval as per INSPPIRE criteria for ARP, and the majority of our patients with ARP progressed within 5 months (14) . Based on these results, we hypothesized that progression within 3 months may signify a ''rapid progression,'' and could represent a distinct group of pancreatitis patients. Our comparison of the patients who progressed rapidly compared to those who did not revealed that they were more likely to be of male sex, have a higher weight percentile for age, and present with pancreatic necrosis during their first attack.
Sex has not been previously associated with risk of AP, ARP, or CP (16) . Obesity has been identified as a risk factor for biliary pancreatitis in pediatric (27) and adult AP, and is a well described risk factor for development of AP and severe AP complications (27) (28) (29) (30) (31) . Data in adults have not shown an association between increased weight and increased risk of progression from AP to ARP or CP. These findings may be relevant to clinical care given the existing high burden of obesity in children (26) . There is significant association between pancreatic necrosis present at first AP attack and subsequent rapid progression to ARP within three months. Necrotizing pancreatitis in children is known to be associated with severe early and chronic complications, including the development of decline in pancreatic function (32) . A recent retrospective study from China also showed increased rates of pancreatic necrosis at first presentation of AP in patients that progressed to ARP/CP (33) . In adults, pancreatic necrosis at first AP presentation was associated with progression to CP (34) .
Our results support the hypothesis that genetic predisposition is one of the strongest risk factors underlying ARP, and testing once the patient meets criteria for ARP is indicated. Patients with multiple etiologies at the time of their first AP attack had a higher risk for progression to ARP than those with only 1 etiology (nongenetic). This is physiologically plausible because there are ''multiple hits'' present in 1 patient, triggering a cycle of recurrent episodes of pancreatitis, rather than one, discrete cause of pancreatic inflammation.
Although this is the first pediatric prospective study on AP progression to ARP, there are limitations to our study worth noting. This study is cross-sectional, with a retrospective analysis of prospectively collected data. It is single centered; therefore, the sample size is limited, and results may not be generalizable. Our center is a quaternary care center, which may bias our population toward sicker patients who may progress to ARP more quickly. In addition, there were a small number of patients with recurrent disease, which may also have biased our results. As previously noted, only a subset of our patients had undergone genetic testing at the time of analysis, so conclusions drawn on genetic results are representative of those patients tested, rather than the entire cohort of patients with pancreatitis. Finally, it is unknown how many total patients were diagnosed with AP during the study period because patients were not enrolled for the study if the managing team or the patient refused. Therefore, it is unclear whether the selection of patients based on enrollment biased the overall patient population for the study. 
CONCLUSIONS
We describe the findings from the first prospective database developed to study the natural history of AP and its progression to ARP in children in the United States. Findings suggest that amongst all children with pancreatitis, there is a clinically distinct cohort of patients who progress rapidly from AP to ARP. Those who rapidly progress are more likely to be of male sex, have a higher weight percentile for age, and present with pancreatic necrosis during their first attack. We will continue to follow our cohort of patients to further our learning of the natural history of AP and progression to ARP. Further studies on the role of genetics and risk factors that lead to ARP progression are needed in the future.
